Listening Well And Early To The Signs Of Alzheimer’s Disease
Executive Summary
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
You may also be interested in...
Podcast: Creating A Digital Biotech Story
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
20 Years After First FDA Filing, Gepirone Finally Approaches Depression Market
Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder.